CL2014000641A1 - Compuestos derivados de triazolo[1,5-a]piridina, inhibidores de la ped10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de enfermedades tales como esquizofrenia, parkinson, alzheimer, entre otras. - Google Patents
Compuestos derivados de triazolo[1,5-a]piridina, inhibidores de la ped10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de enfermedades tales como esquizofrenia, parkinson, alzheimer, entre otras.Info
- Publication number
- CL2014000641A1 CL2014000641A1 CL2014000641A CL2014000641A CL2014000641A1 CL 2014000641 A1 CL2014000641 A1 CL 2014000641A1 CL 2014000641 A CL2014000641 A CL 2014000641A CL 2014000641 A CL2014000641 A CL 2014000641A CL 2014000641 A1 CL2014000641 A1 CL 2014000641A1
- Authority
- CL
- Chile
- Prior art keywords
- ped10a
- triazolo
- schizophrenia
- parkinson
- prophylaxis
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000011321 prophylaxis Methods 0.000 title 1
- 201000000980 schizophrenia Diseases 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
- AQWOIRBQLOOZGX-UHFFFAOYSA-N triazolo[1,5-a]pyridine Chemical compound C1=CC=CC2=CN=NN21 AQWOIRBQLOOZGX-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11181752 | 2011-09-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014000641A1 true CL2014000641A1 (es) | 2014-11-14 |
Family
ID=46851999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014000641A CL2014000641A1 (es) | 2011-09-19 | 2014-03-17 | Compuestos derivados de triazolo[1,5-a]piridina, inhibidores de la ped10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de enfermedades tales como esquizofrenia, parkinson, alzheimer, entre otras. |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US8946427B2 (enExample) |
| EP (1) | EP2758396B1 (enExample) |
| JP (1) | JP2014526533A (enExample) |
| KR (1) | KR101584925B1 (enExample) |
| CN (1) | CN103827114B (enExample) |
| AU (1) | AU2012311713A1 (enExample) |
| BR (1) | BR112014006248A2 (enExample) |
| CA (1) | CA2846758C (enExample) |
| CL (1) | CL2014000641A1 (enExample) |
| CO (1) | CO6900144A2 (enExample) |
| EA (1) | EA201490599A1 (enExample) |
| ES (1) | ES2626801T3 (enExample) |
| IL (1) | IL231403A0 (enExample) |
| MX (1) | MX2014003025A (enExample) |
| PE (1) | PE20141553A1 (enExample) |
| PH (1) | PH12014500499A1 (enExample) |
| SG (1) | SG11201400759RA (enExample) |
| UA (1) | UA108711C2 (enExample) |
| WO (1) | WO2013041472A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140235667A1 (en) | 2011-09-22 | 2014-08-21 | Merck Sharp & Dohme Corp. | Imidazopyridyl compounds as aldosterone synthase inhibitors |
| US9193724B2 (en) | 2011-09-22 | 2015-11-24 | Merck Sharp & Dohme Corp. | Triazolopyridyl compounds as aldosterone synthase inhibitors |
| JP2016520047A (ja) * | 2013-04-30 | 2016-07-11 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ピラゾールアミドのＰｄ触媒カップリング |
| TWI652014B (zh) | 2013-09-13 | 2019-03-01 | 美商艾佛艾姆希公司 | 雜環取代之雙環唑殺蟲劑 |
| WO2016017719A1 (ja) * | 2014-07-30 | 2016-02-04 | 持田製薬株式会社 | ピラゾール誘導体の製造方法 |
| WO2016017711A1 (ja) * | 2014-07-30 | 2016-02-04 | 持田製薬株式会社 | ピラゾール誘導体の製造方法 |
| CN112608300B (zh) | 2015-03-11 | 2024-04-26 | Fmc公司 | 杂环取代的二环唑杀有害生物剂 |
| JP6740239B2 (ja) | 2015-03-12 | 2020-08-12 | エフ エム シー コーポレーションＦｍｃ Ｃｏｒｐｏｒａｔｉｏｎ | 複素環置換二環式アゾール殺有害生物剤 |
| JP6937748B2 (ja) | 2015-10-08 | 2021-09-22 | エフ エム シー コーポレーションＦｍｃ Ｃｏｒｐｏｒａｔｉｏｎ | 複素環で置換した二環式アゾール有害生物防除剤 |
| WO2019038195A1 (de) | 2017-08-22 | 2019-02-28 | Bayer Aktiengesellschaft | Heterocyclen-derivate als schädlingsbekämpfungsmittel |
| CN113906024B (zh) | 2019-05-27 | 2023-10-20 | 日本农药株式会社 | 交联部有氮原子的缩合杂环化合物或其盐类及含该化合物的农业园艺用杀虫剂及其使用方法 |
| AR119140A1 (es) | 2019-06-13 | 2021-11-24 | Pi Industries Ltd | Compuestos heterocíclicos fusionados y su uso como agentes de control de plagas |
| CN110396157B (zh) * | 2019-08-07 | 2021-07-30 | 广州市建筑科学研究院有限公司 | 缓释型聚羧酸纳米减水剂及其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6355653B1 (en) * | 1999-09-06 | 2002-03-12 | Hoffmann-La Roche Inc. | Amino-triazolopyridine derivatives |
| WO2005012485A2 (en) | 2003-07-31 | 2005-02-10 | Bayer Pharmaceuticals Corporation | Methods for treating diabetes and related disorders using pde10a inhibitors |
| NL2000397C2 (nl) * | 2006-01-05 | 2007-10-30 | Pfizer Prod Inc | Bicyclische heteroarylverbindingen als PDE10 inhibitoren. |
| EP2348018A4 (en) * | 2008-09-25 | 2012-04-25 | Kyorin Seiyaku Kk | HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR CONTAINING ACTIVE SUBSTANCE |
| WO2010059836A1 (en) * | 2008-11-20 | 2010-05-27 | Decode Genetics Ehf | Substituted aza-bridged bicyclics for cardiovascular and cns disease |
| US8685967B2 (en) * | 2009-04-07 | 2014-04-01 | Merck Sharp & Dohme Corp. | Substituted triazolopyridines and analogs thereof |
| PL2480546T3 (pl) * | 2009-09-24 | 2015-05-29 | Hoffmann La Roche | Pochodne imidazopirydyny i imidazopirymidyny jako inhibitory fosfodiesterazy 10A |
| CN112019976B (zh) | 2009-11-24 | 2024-09-27 | 诺基亚技术有限公司 | 用于处理音频信号的设备和方法 |
| TWI487705B (zh) * | 2009-12-17 | 2015-06-11 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基三唑衍生物 |
| TW201200516A (en) * | 2009-12-17 | 2012-01-01 | Lundbeck & Co As H | Phenylimidazole derivatives comprising an ethynylene linker as PDE10A enzyme inhibitors |
| TWI485151B (zh) * | 2009-12-17 | 2015-05-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物 |
-
2012
- 2012-09-17 CA CA2846758A patent/CA2846758C/en not_active Expired - Fee Related
- 2012-09-17 ES ES12759445.5T patent/ES2626801T3/es active Active
- 2012-09-17 EA EA201490599A patent/EA201490599A1/ru unknown
- 2012-09-17 BR BR112014006248A patent/BR112014006248A2/pt not_active IP Right Cessation
- 2012-09-17 CN CN201280045398.XA patent/CN103827114B/zh not_active Expired - Fee Related
- 2012-09-17 KR KR1020147009588A patent/KR101584925B1/ko not_active Expired - Fee Related
- 2012-09-17 SG SG11201400759RA patent/SG11201400759RA/en unknown
- 2012-09-17 EP EP12759445.5A patent/EP2758396B1/en not_active Not-in-force
- 2012-09-17 PH PH1/2014/500499A patent/PH12014500499A1/en unknown
- 2012-09-17 PE PE2014000366A patent/PE20141553A1/es not_active Application Discontinuation
- 2012-09-17 JP JP2014531187A patent/JP2014526533A/ja active Pending
- 2012-09-17 AU AU2012311713A patent/AU2012311713A1/en not_active Abandoned
- 2012-09-17 UA UAA201404029A patent/UA108711C2/uk unknown
- 2012-09-17 WO PCT/EP2012/068203 patent/WO2013041472A1/en not_active Ceased
- 2012-09-17 MX MX2014003025A patent/MX2014003025A/es active IP Right Grant
-
2014
- 2014-03-05 CO CO14047250A patent/CO6900144A2/es unknown
- 2014-03-06 IL IL231403A patent/IL231403A0/en unknown
- 2014-03-17 CL CL2014000641A patent/CL2014000641A1/es unknown
- 2014-03-18 US US14/218,275 patent/US8946427B2/en not_active Expired - Fee Related
- 2014-12-16 US US14/572,312 patent/US9227970B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN103827114A (zh) | 2014-05-28 |
| EP2758396B1 (en) | 2017-03-29 |
| BR112014006248A2 (pt) | 2017-04-11 |
| US20150099735A1 (en) | 2015-04-09 |
| PH12014500499A1 (en) | 2014-04-14 |
| KR101584925B1 (ko) | 2016-01-12 |
| EP2758396A1 (en) | 2014-07-30 |
| CA2846758C (en) | 2017-09-12 |
| NZ621597A (en) | 2015-04-24 |
| US9227970B2 (en) | 2016-01-05 |
| SG11201400759RA (en) | 2014-07-30 |
| JP2014526533A (ja) | 2014-10-06 |
| CA2846758A1 (en) | 2013-03-28 |
| MX2014003025A (es) | 2014-05-28 |
| PE20141553A1 (es) | 2014-10-30 |
| KR20140075716A (ko) | 2014-06-19 |
| AU2012311713A1 (en) | 2014-03-13 |
| UA108711C2 (uk) | 2015-05-25 |
| IL231403A0 (en) | 2014-04-30 |
| CN103827114B (zh) | 2016-08-24 |
| US8946427B2 (en) | 2015-02-03 |
| WO2013041472A1 (en) | 2013-03-28 |
| CO6900144A2 (es) | 2014-03-20 |
| ES2626801T3 (es) | 2017-07-26 |
| US20140303141A1 (en) | 2014-10-09 |
| EA201490599A1 (ru) | 2014-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2014001752A1 (es) | Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras. | |
| PH12015500988B1 (en) | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use | |
| CL2014001090A1 (es) | Compuestos derivados de oxazolidinona biciclica; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como aterosclerosis y dislipidemia. | |
| CL2014002386A1 (es) | Compuesto inhibidor de cinasa de fosfoinositida 3 en forma anhidra cristalina solida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento o prevencion de enfermedades tales como epoc, asma, entre otras. | |
| CL2013001891A1 (es) | Compuestos heterociclicos fusionados; composicion farmaceutica y uso en el tratamiento de la degeneracion macular asociada con la edad. | |
| CL2011000668A1 (es) | Compuestos derivados de pirazolopiridina; proceso de preparacion; composicion farmaceutica y uso en el tratamiento de enfermedades tales como artritis reumatoide, psoriasis, esclerosis multiple, entre otras. | |
| CL2015001731A1 (es) | Compuestos inhibidores de autotaxina; composicion y combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como fibrosis, prurito, cancer, entre otras. | |
| CL2014000511A1 (es) | Compuestos derivados de quinazolina, inhibidores selectivos y reversibles de la proteasa especifica de ubiquitina 7; proceso de preparacion; composiciones farmaceuticas que los contienen y el uso en el tratamiento y/o la prevencion de enfermedades tales como cancer. | |
| CL2015001818A1 (es) | Compuestos derivados de azaindol, inhibidores de las proteina quinasas; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer de higado, cancer pancreatico, cancer de pulmon, cancer de mama, leucemias, entre otras. | |
| CL2013001591A1 (es) | Compuestos derivados de triazolopiridina; inhibidores de pde10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, entre otras enfermedades. | |
| CL2013003472A1 (es) | Compuestos derivados de halogenoalquil-1,3-oxazinas sustituidas, inhibidores de la bace1 y/o bace2; procedimiento de obtencion; composicion farmaceutica que los comprende; su uso en el tratamiento y/o profilaxis de enfermedades tales como diabetes, alzheimer, als, enfermedades autoinmunes inflamatorias, cancer, entre otras. | |
| CL2013002125A1 (es) | Compuestos derivados de imidazo[5,1-f][1,2,4]triazinas; composicion farmaceutica; y uso en el tratamiento del deterioro cognitivo asociado con esquizofrenia. | |
| CL2012001073A1 (es) | Compuestos derivados de pirido[4,3-d]pirimidin-5-ona, sus composiciones farmaceuticas y su uso como inhibidores de quinasa para tratar asma, epoc, colitis ulcerante, bronquitis, lupus, cancer de mamas, enfermedad de alzheimer, enfermedad de parkinson, osteoporosis, esclerosis multiple, diabetes, trastornos oculares, restenosis, enfermedades inflamatorias. | |
| PH12015500758A1 (en) | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases | |
| CL2016001629A1 (es) | Compuestos tricíclicos como agentes anticancerígenos | |
| CL2012003604A1 (es) | Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros. | |
| NZ626937A (en) | Fused tetra or penta-cyclic pyridophthalazinones as parp inhibitors | |
| CL2013001464A1 (es) | Compuestos derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina, como inhibidores de jak; composicion farmaceutica que los comprende; producto de combinacion; y su uso en el tratamiento de enfermedades mieloproliferativas, leucemia, enfermedades mediadas por el sistema inmune y enfermedades inflamatorias, entre otras. | |
| CL2013002177A1 (es) | Compuestos derivados de 9h-purinas y 7h-pirrolo[2,3-d]-pirimidinas sustituidas, inhibidores de la pi3k de clase i y/o mtor; su composicon farmaceutica; su combinacion farmaceutica; y su uso en el tratamiento o la prevencion del cancer o trastornos neurodegenerativos. | |
| CL2012003427A1 (es) | Compuestos derivados de 5-amino-3,6-dihidro-1h-pirazina-2-ona; y uso en el tratamiento de enfermedades tales como alzheimer, senilidad, demencia, entre otras. | |
| CL2013003372A1 (es) | Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes. | |
| MX349004B (es) | Nuevos compuestos. | |
| PL2935274T3 (pl) | Pochodne 3-okso-2,3,5,8-tetrahydro-[1,2,4]triazolo[4,3-a]pirymidyny do leczenia chorób układu oddechowego | |
| CL2015003444A1 (es) | Compuestos de 3,4 dihidroisoquinolin-2(1h)-ilo | |
| CL2012002487A1 (es) | Compuestos derivados de imidazo[1,2-a]pirazina, inhibidores de pde10; composicion farmacéutica que los comprende; proceso para preparar la composicion farmaceutica; utiles para el tratamiento de enfermedades neurológicas, psiquiátricas o metabólicas tales como esquizofrenia, parkinson y diabetes, entre otras. |